Regeneron Pharmaceuticals Inc (REGN)

Gross profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Gross profit (ttm) US$ in thousands 10,203,900 7,697,000 7,334,100 7,195,500 7,154,000 11,286,100 11,899,500 14,120,400 13,727,400 12,055,800 11,041,700 8,066,200 7,412,500 7,159,100 6,835,400 6,746,100 6,584,600 6,342,900 6,012,570 5,744,090
Revenue (ttm) US$ in thousands 13,044,200 13,025,200 12,601,200 12,306,100 12,113,500 13,654,100 14,171,800 16,451,800 16,014,400 13,499,700 12,328,800 9,147,000 8,455,000 8,201,600 7,974,500 7,957,900 7,839,900 7,598,200 7,213,600 6,889,000
Gross profit margin 78.23% 59.09% 58.20% 58.47% 59.06% 82.66% 83.97% 85.83% 85.72% 89.30% 89.56% 88.18% 87.67% 87.29% 85.72% 84.77% 83.99% 83.48% 83.35% 83.38%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $10,203,900K ÷ $13,044,200K
= 78.23%

Regeneron Pharmaceuticals, Inc. has demonstrated a consistently high gross profit margin over the past eight quarters, ranging from 89.11% to 93.52%. This indicates the company has been effectively managing its production costs and generating strong revenues from its core operations. The increasing trend in gross profit margin from Q1 2022 to Q1 2023 suggests improved efficiency in the company's manufacturing processes or higher selling prices for its products. Regeneron's ability to maintain a gross profit margin above 90% in most quarters reflects a strong competitive position and effective cost controls. Overall, the company's gross profit margin performance indicates operational effectiveness and sound financial management.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Gross Profit Margin (Quarterly Data)